| 7.58 -0.09 (-1.17%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.64 | 1-year : | 10.41 |
| Resists | First : | 8.25 | Second : | 8.92 |
| Pivot price | 7.94  |
|||
| Supports | First : | 7.19 | Second : | 5.98 |
| MAs | MA(5) : | 7.52 |
MA(20) : | 8.1 |
| MA(100) : | 6.85 |
MA(250) : | 9.01 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 27.9 |
D(3) : | 22.2 |
| RSI | RSI(14): 44.4 |
|||
| 52-week | High : | 16.62 | Low : | 4.51 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MRVI ] has closed above bottom band by 28.2%. Bollinger Bands are 2.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.6 - 7.65 | 7.65 - 7.7 |
| Low: | 7.21 - 7.26 | 7.26 - 7.3 |
| Close: | 7.51 - 7.59 | 7.59 - 7.66 |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
Tue, 23 Apr 2024
Maravai LifeSciences (NASDAQ:MRVI) Shares Up 8.1% - MarketBeat
Sun, 07 Apr 2024
An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued - Simply Wall St
Mon, 11 Mar 2024
Commit To Purchase Maravai LifeSciences Holdings At $5, Earn 15% Using Options - Nasdaq
Wed, 28 Feb 2024
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable - Simply Wall St
Sat, 24 Feb 2024
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Released Its Annual Results And Analysts Are Updating ... - Yahoo Finance
Fri, 23 Feb 2024
Crude Oil Down 2%; Maravai LifeSciences Shares Spike Higher - Markets Insider
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 132 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 102.2 (%) |
| Shares Short | 5,120 (K) |
| Shares Short P.Month | 6,200 (K) |
| EPS | -0.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.15 |
| Profit Margin | -41.2 % |
| Operating Margin | -9.1 % |
| Return on Assets (ttm) | -0.9 % |
| Return on Equity (ttm) | -16.4 % |
| Qtrly Rev. Growth | -63.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.18 |
| EBITDA (p.s.) | 0.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 126 (M) |
| Levered Free Cash Flow | 44 (M) |
| PE Ratio | -8.43 |
| PEG Ratio | 4.9 |
| Price to Book value | 2.4 |
| Price to Sales | 3.47 |
| Price to Cash Flow | 7.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|